OBJECTIVE: To describe the epidemiology, treatment and adverse events after snakebite in Australia. DESIGN: Prospective, multicentre study of data on patients with snakebites recruited to the Australian Snakebite Project (2005-2015) and data from the National Coronial Information System. Setting, participants: Patients presenting to Australian hospitals with suspected or confirmed snakebites from July 2005 to June 2015 and consenting to participation. MAIN OUTCOME MEASURES: Demographic data, circumstances of bites, clinical effects of envenoming, results of laboratory investigations and snake venom detection kit (SVDK) testing, antivenom treatment and adverse reactions, time to discharge, deaths. RESULTS: 1548 patients with suspected snakebites were enrolled, including 835 envenomed patients (median, 87 per year), for 718 of which the snake type was definitively established, most frequently brown snakes (41%), tiger snakes (17%) and red-bellied black snakes (16%). Clinical effects included venom-induced consumption coagulopathy (73%), myotoxicity (17%), and acute kidney injury (12%); severe complications included cardiac arrest (25 cases; 2.9%) and major haemorrhage (13 cases; 1.6%). There were 23 deaths (median, two per year), attributed to brown (17), tiger (four) and unknown (two) snakes; ten followed out-of-hospital cardiac arrests and six followed intracranial haemorrhages. Of 597 SVDK test results for envenomed patients with confirmed snake type, 29 (4.9%) were incorrect; 133 of 364 SVDK test results for non-envenomed patients (36%) were false positives. 755 patients received antivenom, including 49 non-envenomed patients; 178 (24%), including ten non-envenomed patients, had systemic hypersensitivity reactions, of which 45 (6%) were severe (hypotension, hypoxaemia). Median total antivenom dose declined from four vials to one, but median time to first antivenom was unchanged (4.3 hours; IQR, 2.7-6.3 hours). CONCLUSIONS: Snake envenoming is uncommon in Australia, but is often severe. SVDKs were unreliable for determining snake type. The median antivenom dose has declined without harming patients. Improved early diagnostic strategies are needed to reduce the frequently long delays before antivenom administration.
OBJECTIVE: To describe the epidemiology, treatment and adverse events after snakebite in Australia. DESIGN: Prospective, multicentre study of data on patients with snakebites recruited to the Australian Snakebite Project (2005-2015) and data from the National Coronial Information System. Setting, participants: Patients presenting to Australian hospitals with suspected or confirmed snakebites from July 2005 to June 2015 and consenting to participation. MAIN OUTCOME MEASURES: Demographic data, circumstances of bites, clinical effects of envenoming, results of laboratory investigations and snake venom detection kit (SVDK) testing, antivenom treatment and adverse reactions, time to discharge, deaths. RESULTS: 1548 patients with suspected snakebites were enrolled, including 835 envenomed patients (median, 87 per year), for 718 of which the snake type was definitively established, most frequently brown snakes (41%), tiger snakes (17%) and red-bellied black snakes (16%). Clinical effects included venom-induced consumption coagulopathy (73%), myotoxicity (17%), and acute kidney injury (12%); severe complications included cardiac arrest (25 cases; 2.9%) and major haemorrhage (13 cases; 1.6%). There were 23 deaths (median, two per year), attributed to brown (17), tiger (four) and unknown (two) snakes; ten followed out-of-hospital cardiac arrests and six followed intracranial haemorrhages. Of 597 SVDK test results for envenomed patients with confirmed snake type, 29 (4.9%) were incorrect; 133 of 364 SVDK test results for non-envenomed patients (36%) were false positives. 755 patients received antivenom, including 49 non-envenomed patients; 178 (24%), including ten non-envenomed patients, had systemic hypersensitivity reactions, of which 45 (6%) were severe (hypotension, hypoxaemia). Median total antivenom dose declined from four vials to one, but median time to first antivenom was unchanged (4.3 hours; IQR, 2.7-6.3 hours). CONCLUSIONS: Snake envenoming is uncommon in Australia, but is often severe. SVDKs were unreliable for determining snake type. The median antivenom dose has declined without harming patients. Improved early diagnostic strategies are needed to reduce the frequently long delays before antivenom administration.
Entities:
Keywords:
Adverse drug reactions; Antivenoms; Envenomation; Rural health services; Snakebites
Authors: Elham Esmaeilishirazifard; Louise Usher; Carol Trim; Hubert Denise; Vartul Sangal; Gregory H Tyson; Axel Barlow; Keith F Redway; John D Taylor; Myrto Kremyda-Vlachou; Sam Davies; Teresa D Loftus; Mikaella M G Lock; Kstir Wright; Andrew Dalby; Lori A S Snyder; Wolfgang Wuster; Steve Trim; Sterghios A Moschos Journal: Microbiol Spectr Date: 2022-05-23
Authors: Andrew M Durso; Rafael Ruiz de Castañeda; Camille Montalcini; M Rosa Mondardini; Jose L Fernandez-Marques; François Grey; Martin M Müller; Peter Uetz; Benjamin M Marshall; Russell J Gray; Christopher E Smith; Donald Becker; Michael Pingleton; Jose Louies; Arthur D Abegg; Jeannot Akuboy; Gabriel Alcoba; Jennifer C Daltry; Omar M Entiauspe-Neto; Paul Freed; Marco Antonio de Freitas; Xavier Glaudas; Song Huang; Tianqi Huang; Yatin Kalki; Yosuke Kojima; Anne Laudisoit; Kul Prasad Limbu; José G Martínez-Fonseca; Konrad Mebert; Mark-Oliver Rödel; Sara Ruane; Manuel Ruedi; Andreas Schmitz; Sarah A Tatum; Frank Tillack; Avinash Visvanathan; Wolfgang Wüster; Isabelle Bolon Journal: Toxicon X Date: 2021-06-22
Authors: Rahini Kakumanu; Barbara K Kemp-Harper; Anjana Silva; Sanjaya Kuruppu; Geoffrey K Isbister; Wayne C Hodgson Journal: Sci Rep Date: 2019-12-27 Impact factor: 4.379
Authors: Manuela B Pucca; Cecilie Knudsen; Isadora S Oliveira; Charlotte Rimbault; Felipe A Cerni; Fan Hui Wen; Jacqueline Sachett; Marco A Sartim; Andreas H Laustsen; Wuelton M Monteiro Journal: Toxins (Basel) Date: 2020-10-22 Impact factor: 4.546